Efficacy and safety of Castellani paint and topical timolol for treating epidermal growth factor receptor inhibitors induced paronychia: a randomized, intraindividual study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20251201009

Enrollment

Registered

2025-12-01

Start date

2025-08-25

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Applying Castellani&#039

s paint solution to one nail that has a side effect from EGFRIs, which hasa CTCAE grade 2-3 ,Applying Timolol solution to one nail that has a side effect from EGFRIs, which has a CTCAE grade 2-3

Active Comparator Drug,Active Comparator Drug

Castellani&#039

s paint solution,0.5% Timolol solution

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Cancer patients who received EGFRIs 2. Patients who were diagnosed with nail side effects with 3. CTCAE paronychia grade 2-3 4. Age>= 18 years

Exclusion criteria

Exclusion criteria: 1. Patients who have asthma, COPD 2. Patients who received the nail procedures 3. patients who have neutropenia or thrombocytopenia

Design outcomes

Primary

Measure	Time frame
clearance of the lesion 8 weeks 1.Complete response , 2.Partial response , 3.No response	—

Secondary

Measure	Time frame
Scoring system for Paronychia related to Oncologic Treatments (SPOT), 8 weeks SPOT score	—

Countries

Thailand

Contacts

Public ContactLeena Chularojanamontri

Department of Dermatology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Thailand

info.sirirajderm@gmail.com024197000

Outcome results